Τίτλος:
Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: Results of a pooled analysis of non-interventional studies
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Aim To assess the efficacy and safety of everolimus in patients with metastatic renal cell carcinoma (mRCC) who failed one or two anti-VEGF therapies. Patients and methods Data from four prospective, non-interventional studies conducted in Germany, France, Greece and Austria were pooled for this analysis. Patients with mRCC of any histology (clear cell or non-clear cell) were included. VEGF-refractory patients received everolimus 10 mg/day until disease progression or unacceptable toxicity. The primary objective was to determine everolimus efficacy as measured by time to progression (TTP; from baseline to progression). Results The overall population comprised 632 patients; 493 patients received everolimus in the second-line setting. Most patients were of favourable/intermediate MSKCC risk (91%), had clear cell mRCC (89%), and had undergone nephrectomy (89%). Median TTP was 6.3 months (95% confidence interval [CI], 5.9-6.8) for the overall population and 6.4 months (95% CI, 5.8-6.9) for the second-line everolimus population. Similarly, median progression-free survival was 5.5 months (95% CI, 5.0-6.1) for the overall population and 5.8 months (95% CI, 5.0-6.4) for second-line everolimus population. Best tumour response (n = 349) was complete or partial remission in 12% of patients and stable disease in 59% of patients. Overall population median overall survival (OS) was 11.2 months (95% CI, 9.0-not reached). Commonly reported adverse events (AEs) (any grade) were stomatitis (25%), anaemia (15%) and asthenia (11%). Conclusions Results of this pooled analysis provide evidence of safety and effectiveness of second-line everolimus in routine clinical use and support everolimus as a standard of care for VEGF-refractory patients with mRCC. © 2015 Elsevier Ltd. All rights reserved.
Συγγραφείς:
Albiges, L.
Kube, U.
Eymard, J.-C.
Schmidinger, M.
Bamias, A.
Kelkouli, N.
Mraz, B.
Florini, S.
Guderian, G.
Cattaneo, A.
Bergmann, L.
Περιοδικό:
EUROPEAN JOURNAL OF CANCER
Εκδότης:
Elsevier Ireland Ltd
Λέξεις-κλειδιά:
bevacizumab; everolimus; sorafenib; sunitinib; angiogenesis inhibitor; everolimus; vasculotropin A, adult; aged; anemia; Article; asthenia; Austria; cancer patient; cancer regression; cancer survival; coughing; decreased appetite; diarrhea; disease course; drug efficacy; drug eruption; drug safety; drug treatment failure; dyspnea; epistaxis; fatigue; female; fever; follow up; France; Germany; Greece; human; hyperglycemia; hypertriglyceridemia; kidney metastasis; major clinical study; male; malignant neoplastic disease; nausea; neoplasm; nephrectomy; peripheral edema; pleura effusion; pneumonia; priority journal; stomatitis; adjuvant chemotherapy; adolescent; antagonists and inhibitors; Carcinoma, Renal Cell; disease free survival; drug resistance; Europe; Kaplan Meier method; Kidney Neoplasms; meta analysis; metabolism; middle aged; pathology; risk factor; secondary; time; treatment outcome; very elderly; young adult, Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Europe; Everolimus; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Risk Factors; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A; Young Adult
DOI:
10.1016/j.ejca.2015.07.030
